Basilea Pharmaceutica Ltd. Logo
 
Home
 
 
Search
 
 
 

Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. Basilea is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions.

 
News
 
 
Language
 
Tuesday, May 15. 2018
 
Basel, Switzerland, May 15, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that its partner Hikma Pharmaceuticals LLC has launched Basilea's hospital antibiotic Zevtera® (ceftobiprole) in Saudi Arabia.
 
more...
 
Friday, April 27. 2018
 
  • Dr. Gerrit Hauck appointed as Chief Technology Officer, succeeding Dr. Günter Ditzinger who will take on new responsibilities at Basilea
  • Dr. Anne Stehlin succeeding Dr. Josef Künzle as Head of Global Quality Management upon his retirement
 
more...
 
Friday, April 20. 2018
 
Basel, Switzerland, April 20, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that a broad range of posters and presentations on the antifungal isavuconazole (Cresemba®) and the antibiotic ceftobiprole (Zevtera®) will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which will be held in Madrid, Spain, from April 21 to 24, 2018.
 
more...
 
Wednesday, April 18. 2018
 
Basel, Switzerland, April 18, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported that shareholders approved all proposals of the Board of Directors at today's Annual General Meeting of Shareholders (AGM) for the financial year 2017.The shareholders approved the annual report, the financial statements, and consolidated financial statements for the financial year 2017, and approved the discharge of the members of Basilea's Board of Directors and Management Committee. Shareholders also approved carrying forward the accumulated deficit, and re-elected PricewaterhouseCoopers AG, Basel, as auditors.
 
more...
 
Info
 
 
 

Quick links:

Investor calendar
Upcoming events
 


News subscription
Press releases via e-mail
 


French Sunshine Act
Transparence des liens d’intérêt